Rapid respiratory microbiological point-of-care-testing and antibiotic prescribing in primary care: Protocol for the RAPID-TEST randomised controlled trial.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 21 03 2024
accepted: 28 03 2024
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 20 5 2024
Statut: epublish

Résumé

Antibiotics are prescribed for over 50% of respiratory tract infections in primary care, despite good evidence of there being no benefit to the patient, and evidence of over prescribing driving microbial resistance. The high treatment rates are attributed to uncertainty regarding microbiological cause and clinical prognosis. Point-of-care-tests have been proposed as potential antibiotic stewardship tools, with some providing microbiological results in 15 minutes. However, there is little research on their impact on antibiotic use and clinical outcomes in primary care. This is a multi-centre, individually randomised controlled trial with mixed-methods investigation of microbial, behavioural and antibiotic mechanisms on outcomes in patients aged 12 months and over presenting to primary care in the UK with a suspected respiratory tract infection, where the clinician and/or patient thinks antibiotic treatment may be, or is, necessary. Once consented, all participants are asked to provide a combined nose and throat swab sample and randomised to have a rapid microbiological point-of-care-test or no point-of-care-test. For intervention patients, clinicians review the result of the test, before contacting the patient to finalise treatment. Treatment decisions are made as per usual care in control group patients. The primary outcome is whether an antibiotic is prescribed at this point. All swab samples are sent to the central laboratory for further testing. Patients are asked to complete a diary to record the severity and duration of symptoms until resolution or day 28, and questionnaires at 2 months about their beliefs and intention to consult for similar future illnesses. Primary care medical records are also reviewed at 6-months to collect further infection consultations, antibiotic prescribing and hospital admissions. The trial aims to recruit 514 patients to achieve 90% power with 5% significance to detect a 15% absolute reduction in antibiotic prescribing. Qualitative interviews are being conducted with approximately 20 clinicians and 30 participants to understand any changes in beliefs and behaviour resulting from the point-of-care-test and generate attributes for clinician and patient discrete choice experiments. This trial will provide evidence of efficacy, acceptability and mechanisms of action of a rapid microbiological point-of-care test on antibiotic prescribing and patient symptoms in primary care. ISRCTN16039192, prospectively registered on 08/11/2022.

Sections du résumé

BACKGROUND BACKGROUND
Antibiotics are prescribed for over 50% of respiratory tract infections in primary care, despite good evidence of there being no benefit to the patient, and evidence of over prescribing driving microbial resistance. The high treatment rates are attributed to uncertainty regarding microbiological cause and clinical prognosis. Point-of-care-tests have been proposed as potential antibiotic stewardship tools, with some providing microbiological results in 15 minutes. However, there is little research on their impact on antibiotic use and clinical outcomes in primary care.
METHODS METHODS
This is a multi-centre, individually randomised controlled trial with mixed-methods investigation of microbial, behavioural and antibiotic mechanisms on outcomes in patients aged 12 months and over presenting to primary care in the UK with a suspected respiratory tract infection, where the clinician and/or patient thinks antibiotic treatment may be, or is, necessary. Once consented, all participants are asked to provide a combined nose and throat swab sample and randomised to have a rapid microbiological point-of-care-test or no point-of-care-test. For intervention patients, clinicians review the result of the test, before contacting the patient to finalise treatment. Treatment decisions are made as per usual care in control group patients. The primary outcome is whether an antibiotic is prescribed at this point. All swab samples are sent to the central laboratory for further testing. Patients are asked to complete a diary to record the severity and duration of symptoms until resolution or day 28, and questionnaires at 2 months about their beliefs and intention to consult for similar future illnesses. Primary care medical records are also reviewed at 6-months to collect further infection consultations, antibiotic prescribing and hospital admissions. The trial aims to recruit 514 patients to achieve 90% power with 5% significance to detect a 15% absolute reduction in antibiotic prescribing. Qualitative interviews are being conducted with approximately 20 clinicians and 30 participants to understand any changes in beliefs and behaviour resulting from the point-of-care-test and generate attributes for clinician and patient discrete choice experiments.
DISCUSSION CONCLUSIONS
This trial will provide evidence of efficacy, acceptability and mechanisms of action of a rapid microbiological point-of-care test on antibiotic prescribing and patient symptoms in primary care.
TRIAL REGISTRATION BACKGROUND
ISRCTN16039192, prospectively registered on 08/11/2022.

Identifiants

pubmed: 38768129
doi: 10.1371/journal.pone.0302302
pii: PONE-D-24-09839
doi:

Types de publication

Journal Article Randomized Controlled Trial Multicenter Study Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0302302

Informations de copyright

Copyright: © 2024 Abbs et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Samantha Elizabeth Abbs (SE)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Lindsay Armstrong-Buisseret (L)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Kathy Eastwood (K)

Patient Representative, United Kingdom.

Stephen Granier (S)

Whiteladies Medical Group, Bristol, United Kingdom.

Athene Lane (A)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Mandy Lui (M)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Chris Metcalfe (C)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Paul Mitchell (P)

Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Peter Muir (P)

UKHSA South West Regional Laboratory, Southmead Hospital, Bristol, United Kingdom.

Matthew Ridd (M)

Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Jodi Taylor (J)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Lucy Yardley (L)

School of Psychological Science, University of Bristol, Bristol, United Kingdom.
School of Psychology, University of Southampton, Southampton, United Kingdom.

Grace Young (G)

Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Alastair D Hay (AD)

Centre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH